Efficacy and Safety of Zerafil ® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
Conditions: Allergic Asthma; Uncontrolled Moderate to Severe Interventions: Biological: Omalizumab (CinnaGen); Biological: Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland) Sponsor: Cinnagen Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials